Cargando…

Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Dani Ran, Park, Daniel, Jeon, Won Jin, Joung, Bowon, Lee, Jae, Yang, Chieh, Pham, Bryan, Hino, Christopher, Chong, Esther, Shields, Andrea, Nguyen, Anthony, Brothers, Joel, Liu, Yan, Zhang, Ke K., Cao, Huynh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298847/
https://www.ncbi.nlm.nih.gov/pubmed/37373354
http://dx.doi.org/10.3390/ijms241210207
_version_ 1785064217680805888
author Castillo, Dani Ran
Park, Daniel
Jeon, Won Jin
Joung, Bowon
Lee, Jae
Yang, Chieh
Pham, Bryan
Hino, Christopher
Chong, Esther
Shields, Andrea
Nguyen, Anthony
Brothers, Joel
Liu, Yan
Zhang, Ke K.
Cao, Huynh
author_facet Castillo, Dani Ran
Park, Daniel
Jeon, Won Jin
Joung, Bowon
Lee, Jae
Yang, Chieh
Pham, Bryan
Hino, Christopher
Chong, Esther
Shields, Andrea
Nguyen, Anthony
Brothers, Joel
Liu, Yan
Zhang, Ke K.
Cao, Huynh
author_sort Castillo, Dani Ran
collection PubMed
description Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6− MCL. 2. BCL6+/CD10+ vs. BCL6−/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan–Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. BCL6+/CD10− MCL (median OS: 20 months vs. 55 months p = 0.1828), BCL6+ MCL had significantly higher percentages of Ki67% (Ki67% difference: 24.29; p = 0.0094), and BCL6 positivity had a positive correlation with CD10+ status with an odds ratio 5.11 (2.49, 10.46; p = 0.0000286). Our analysis showed that BCL6 expression is correlated with CD10 positivity in MCL, and BCL6 expression demonstrated an inferior overall survival. The higher Ki67 PI in BCL6+ MCL compared to BCL6− MCL further supports the idea that the BCL6+ immunophenotype may have prognostic value in MCL. MCL management should consider incorporating prognostic scoring systems adjusted for BCL6 expression. Targeted therapies against BCL6 may offer potential therapeutic options for managing MCL with aberrant immunophenotypes.
format Online
Article
Text
id pubmed-10298847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102988472023-06-28 Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review Castillo, Dani Ran Park, Daniel Jeon, Won Jin Joung, Bowon Lee, Jae Yang, Chieh Pham, Bryan Hino, Christopher Chong, Esther Shields, Andrea Nguyen, Anthony Brothers, Joel Liu, Yan Zhang, Ke K. Cao, Huynh Int J Mol Sci Review Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6− MCL. 2. BCL6+/CD10+ vs. BCL6−/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan–Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. BCL6+/CD10− MCL (median OS: 20 months vs. 55 months p = 0.1828), BCL6+ MCL had significantly higher percentages of Ki67% (Ki67% difference: 24.29; p = 0.0094), and BCL6 positivity had a positive correlation with CD10+ status with an odds ratio 5.11 (2.49, 10.46; p = 0.0000286). Our analysis showed that BCL6 expression is correlated with CD10 positivity in MCL, and BCL6 expression demonstrated an inferior overall survival. The higher Ki67 PI in BCL6+ MCL compared to BCL6− MCL further supports the idea that the BCL6+ immunophenotype may have prognostic value in MCL. MCL management should consider incorporating prognostic scoring systems adjusted for BCL6 expression. Targeted therapies against BCL6 may offer potential therapeutic options for managing MCL with aberrant immunophenotypes. MDPI 2023-06-16 /pmc/articles/PMC10298847/ /pubmed/37373354 http://dx.doi.org/10.3390/ijms241210207 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Castillo, Dani Ran
Park, Daniel
Jeon, Won Jin
Joung, Bowon
Lee, Jae
Yang, Chieh
Pham, Bryan
Hino, Christopher
Chong, Esther
Shields, Andrea
Nguyen, Anthony
Brothers, Joel
Liu, Yan
Zhang, Ke K.
Cao, Huynh
Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title_full Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title_fullStr Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title_full_unstemmed Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title_short Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
title_sort unveiling the prognostic significance of bcl6+/cd10+ mantle cell lymphoma: meta-analysis of individual patients and systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298847/
https://www.ncbi.nlm.nih.gov/pubmed/37373354
http://dx.doi.org/10.3390/ijms241210207
work_keys_str_mv AT castillodaniran unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT parkdaniel unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT jeonwonjin unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT joungbowon unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT leejae unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT yangchieh unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT phambryan unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT hinochristopher unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT chongesther unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT shieldsandrea unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT nguyenanthony unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT brothersjoel unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT liuyan unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT zhangkek unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview
AT caohuynh unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview